Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03161899|
Recruitment Status : Not yet recruiting
First Posted : May 22, 2017
Last Update Posted : July 19, 2017
Thalassemia is a blood disorder passed down through families in which the body makes an abnormal form of hemoglobin. There are 2 main types of thalassemia; Alpha & Beta thalassemia. Alpha thalassemia: occurs when a gene or genes related to the alpha globin protein are missing or mutated.
Beta-thalassemia syndromes are a group of hereditary blood disorders characterized by reduced or absent beta globin chain synthesis. Beta-thalassemias can be classified into:
Silent carrier: completely asymptomatic with normal hematological parameters. Beta-thalassaemia minor (beta-thalassaemia trait): usually asymptomatic; diagnosis is made during a work-up for mild anemia.
Beta-thalassaemia intermedia: usually a similar presentation to beta-thalassaemia major; symptoms are usually less pronounced and the course is usually more insidious.
Beta-thalassaemia major : In which there is complete absence of hemoglobin A
|Condition or disease|
In Egypt beta thalassemia-major is the most common type with carrier rate of 5.3 to ≥9%and 1000 new cases born with beta-thalassemia major per 1.5 million live births per year.
Children born with thalassemia major are normal at birth, but develop severe hemolytic anemia during the first year of life. Symptoms are those of anemia (lethargy, poor feeding, pallor…etc.) failure to thrive and organomegaly. Later on they develop signs of extra medullary hematopoiesis .
Optimal nutritional status is important for growth, immune function, bone health and pubertal development . Various reports suggest the incidence of poor growth ranges from 25% to 75% depending on thalassemia syndrome and severity of disease. This marked growth deficits raise a red ﬂag for any pediatrician to evaluate nutritional status of thalassemic patients and detect possible nutritional deficiencies and associated factors.
Etiology of delayed growth and malnutrition reported in thalassemic patient is multifactorial including :
- Nutritional deprivation with or without feeding difficulties arising from fatigue and breathlessness
- Increased energy expenditure secondary to hyper metabolism with or without heart failure
- Gastrointestinal hypoxia which consequently produces anorexia and malabsorption
- Reduction of biosynthetic activity of liver.
- Disturbance of the endocrine function
- Impaired synthetic hepatic function secondary to hemosiderosis and hepatitis.
The main aim of this study is to assess the nutritional status of thalassemic patient attending Assiut university Children hospital and to determine the factors involved.
|Study Type :||Observational|
|Estimated Enrollment :||246 participants|
|Official Title:||Evaluation of Nutritional Status in Patients With Thalassemia Major in Assiut University Children Hospital|
|Estimated Study Start Date :||October 2017|
|Estimated Primary Completion Date :||May 31, 2018|
|Estimated Study Completion Date :||December 1, 2018|
- percentage of malnutrition [ Time Frame: 12 month ]prevalence of malnutrition among thalassemic children attending assiut university children hospital
- aetiology poor growth [ Time Frame: 12 month ]determination of the most common causes responsible for poor growth seen in thalassemic patients
- decrease morbidity [ Time Frame: 18 month ]decrease morbidity by providing possible strategies for early prevention of the problem of poor growth occurring in patients with thalassemia major
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03161899
|Contact: Mohammed mahmoud hamdy ghazally, MD||01001296603||Hamdyghazally@yahoo.com|
|Contact: Mervet amin mahmoud, MD||01142606221|
|Principal Investigator:||asmaa refaat, MBBCH||Assuit , faculty of medicine, egypt|